- presentation made by Bioniche Food Safety President regarding EconicheTM,
the world's first fully-licensed cattle vaccine against E. coli O157 -
BELLEVILLE, ON, Feb. 15 /CNW/ - Bioniche Life Sciences Inc. (TSX & ASX:
BNC), a research-based, technology-driven Canadian biopharmaceutical
company, gave a presentation about its E. coli O157 cattle vaccine at the First International One Health Congress in
Melbourne, Victoria, Australia. The Bioniche presentation - by Rick
Culbert, President of Bioniche Food Safety - was focused on the
challenge of implementing cattle vaccination against E. coli O157 to reduce the risk of human infection.
In the One Health Congress presentation, Mr. Culbert noted that E. coli O157 is a global problem that requires a proactive solution. "The fact
that the organism does not make cattle ill presents an adoption
challenge in the cattle industry," said Mr. Culbert. "At the moment,
cattle producers receive no direct benefit or compensation to justify
the cost of vaccination against E. coli O157. However, there is an opportunity for the cattle industry to
collaborate with public health to more effectively deal with this
Most strains of E. coli are harmless but some, like O157, can cause severe illness and can even
be fatal when ingested by humans from contaminated meat, vegetables,
other food products, or water. Human exposure and infection with E. coli O157 can result in serious health consequences, including abdominal
pain and severe bloody diarrhea. In severe cases, kidney damage can
occur and progress to serious complications and even death. Lingering,
long-term medical conditions can persist in individuals exposed to the
bacterium. These include post-infectious irritable bowel syndrome
(PI-IBS), reduced kidney function, diabetes, hypertension and reactive
An E. coli O157 outbreak last fall in the U.S. was associated with the consumption
of raw milk gouda cheese. Last November, seven cases of E. coli O157 human illness in the U.S. were linked to the consumption of apple
cider and eleven cases were linked to the consumption of contaminated
food served at a Thanksgiving dinner. An outbreak last summer at a
restaurant chain in Japan was traced to beef that was imported from
About the Bioniche E. coli O157 Vaccine (EconicheTM)
The Food Safety Division of Bioniche Life Sciences Inc. has worked with
Canadian university researchers to develop and license a cattle vaccine
against E. coli O157. This vaccine - trademarked EconicheTM - is meant to reduce the level of the bacterium in water, food and the
environment and, in turn, reduce the potential infection of humans. It
has been fully licensed in Canada since October, 2008. A conditional
license is pending in the U.S.
EconicheTM has the potential to significantly reduce the amount of E. coli O157 shed into the environment by beef and dairy cattle. This organism
does not cause illness in cattle, but cattle are the primary reservoir
for it. Vaccination of cattle with EconicheTM can help reduce the risk of food and waterborne contamination with E. coli O157.
EconicheTM is manufactured at the Company's Belleville, Ontario site where,
supported by the Ontario and Canadian governments, a $25-million
expansion is taking place that is expected to be completed by the end
of March, 2011.
More about E. coli O157
An estimated 100,000 cases of human infection with the E. coli O157 organism are reported each year in North America. Two to seven per
cent of those people develop haemolytic uremic syndrome (HUS), a
disease characterized by kidney failure. Five percent of HUS patients
die, many of them children and senior citizens, whose kidneys are more
sensitive to damage.
About the First International One Health Congress
The One Health Congress was designed to focus on the disease risks and
challenges brought about by the interactions between animals, humans
and the environment. The goal of the Congress is to review current
disease knowledge at this interface and provide information needed to
more effectively manage the emerging infectious disease risks at
national, regional and global levels. The outcomes include the
identification of future research directions and to make
recommendations on policy and organisational changes using the
underlying science to inform and drive the process.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary products for
human and animal health markets worldwide. The fully-integrated company
employs 218 skilled personnel and has three operating divisions: Human
Health, Animal Health, and Food Safety. The Company's primary goal is
to develop proprietary cancer therapies supported by revenues from
marketed products in human and animal health. For more information,
please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097